Diabetes

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging

News

Novo Nordisk sales surge drives value towards $500bn

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

News

FDA seeks feedback on digital tools for diabetes

The FDA has opened a comment period, extending until the end of the month, that is seeking information on how digital health technologies (DHTs) might be deployed to help

Novo Nordisk looks set to add another string to Ozempic bow

Could Novo-Catalent deal face antitrust hurdles?

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk sales surge drives value towards $500bn

Britain will be first to get new Mounjaro device, says Lilly

FDA seeks feedback on digital tools for diabetes

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Diabetes

Editor's Picks